Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy

Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy

Immunosuppressive therapy plays an important role in patients with high-risk idiopathic membranous nephropathy (IMN), but the therapeutic modality is still controversial. Methods: Corticosteroid combined with oral tacrolimus (TAC, target trough blood concentration of 4–8 ng/mL), intravenous cyclopho...

Full description

Bibliographic Details
Main Authors:	Lei Peng, Shi-Yao Wei, Lei-Ting Li, Yi-Xin He, Bing Li
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Journal of the Formosan Medical Association
Subjects:	cyclophosphamide idiopathic membranous nephropathy mycophenolate mofetil proteinuria tacrolimus
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664615002776

Similar Items

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
by: Lin S, et al.
Published: (2019-07-01)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
by: Honghong Zou, et al.
Published: (2019-01-01)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
by: W. Cui, et al.

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
by: Aikaterini Nikolopoulou, et al.
Published: (2019-09-01)

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials
by: Haiting Huang, et al.
Published: (2021-01-01)

Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy
by: Luo Lei, et al.
Published: (2012-07-01)

Mediastinal tuberculous abscess: A rare presentation after renal transplant
by: Sukanto K Das, et al.
Published: (2019-01-01)

Two cases of idiopathic membranous nephropathy treated with rituximab
by: Jae Young Yoon, et al.
Published: (2013-09-01)

Membranous nephropathy: Treatment outline and risk stratification
by: Ziad Arabi
Published: (2012-07-01)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
by: Shun-Lai Shang, et al.
Published: (2018-07-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
by: Bing Du, et al.
Published: (2017-07-01)

Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
by: Arun Sedhain, et al.
Published: (2018-07-01)

Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis
by: Jiatong Li, et al.
Published: (2019-12-01)

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy
by: Lina Shao, et al.
Published: (2019-10-01)

Factors affecting the long-term outcomes of idiopathic membranous nephropathy
by: Hyuk Huh, et al.
Published: (2017-03-01)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
by: Shasha Chen, et al.
Published: (2020-02-01)

Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials
by: AK Ali, et al.
Published: (2011-10-01)

Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy
by: Xinxin Chen, et al.
Published: (2019-01-01)

Long-Term Outcome of Patients with Lupus Nephritis: A Single Center Experience
by: Senija Rašić, et al.
Published: (2010-04-01)

Current and emerging treatment options in the management of lupus
by: Jordan N, et al.
Published: (2016-03-01)

Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy
by: XIE Xinfu, et al.
Published: (2021-06-01)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
by: Lin W, et al.
Published: (2019-07-01)

Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature
by: Yuejuan Pan, et al.
Published: (2020-12-01)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
by: Zhang C, et al.
Published: (2020-04-01)

Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients
by: Mysore K. Phanish, et al.
Published: (2020-03-01)

Successful Treatment of Mucocutaneous Lupus Erythematosus in a Dog with Prednisolone, Mycophenolate Mofetil and Tacrolimus
by: Jae-Eun Hyun, et al.
Published: (2021-04-01)

Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment
by: Dorota Krasowska, et al.
Published: (2017-12-01)

Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy
by: Qi-Jun Wan, et al.
Published: (2015-01-01)

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
by: Anji Xiong, et al.
Published: (2021-03-01)

Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patients—Results From the SAILOR Study
by: Nima Nourbakhsh, et al.
Published: (2021-09-01)

Therapeutic Drug Monitoring in Rheumatic Diseases
by: NG Hoi-Yan Alexandra, et al.
Published: (2016-12-01)

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
by: Raja Ramachandran, et al.
Published: (2017-07-01)

Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study
by: Shefali Khanna Sharma, et al.
Published: (2020-08-01)

Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study
by: Kumar Sanjeev, et al.
Published: (2012-09-01)

Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
by: Wenkai Guo, et al.
Published: (2020-02-01)

Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation
by: Ana Cristina Aoun Tannuri, et al.
Published: (2016-04-01)

Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients
by: R. Garcia, et al.
Published: (2007-04-01)

Experience with second line drugs in frequently relapsing and steroid dependent childhood nephrotic syndrome in a large Saudi center
by: Khalid Alsaran, M.D., et al.
Published: (2017-06-01)

Retrospective comparison of cyclophosphamide and mycophenolate mofetil in lupus nephritis at Groote Schuur Hospital nephrology unit
by: Sogayise, Phelisa
Published: (2021)